You are here: Industry Insights > Bamlanivimab

News List

Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase III trial expresspharma
March 11, 2021
Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorised in the US and several other countries.
EMA Issues Advice on bamlanivimab Alone, Administered Together with etesevimab for COVID-19 in EU americanpharmaceuticalreview
March 10, 2021
Eli Lilly and Company announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab.
Jubilant HollisterStier, Eli Lilly Enter COVID-19 Treatment Collaboration contractpharma
March 10, 2021
The CMO signs manufacturing agreement with Lilly for COVID-19 therapeutic Bamlanivimab.
EMA concludes review of Lilly’s COVID-19 antibody therapies europeanpharmaceuticalreview
March 09, 2021
The human medicines committee decided that there was significant evidence to endorse the use of a combination of bamlanivimab and etesevimab in outpatients at high risk of severe COVID-19.
CHMP issues positive opinion for Lilly’s COVID-19 antibodies pharmatimes
March 08, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Eli Lilly’s COVID-19 antibodies bamlanivimab and etesevimab.
U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail contractpharma
March 02, 2021
The U.S. government will purchase a minimum of 100,000 doses of Lilly’s bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together.
AbCellera gets EUA from US FDA for its antibody Bamlanivimab, along with Etesevimab for COVID-19 expresspharma
February 10, 2021
Lilly plans to manufacture more than 250,000 doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a million doses by mid-2021.
Lilly’s antibodies bamlanivimab and etesevimab show promise against COVID-19 pharmatimes
January 29, 2021
Eli Lilly’s neutralising antibodies bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalisations and deaths in recently diagnosed, high-risk COVID-19 patients.
Bamlanivimab Reduced Risk of COVID-19 at Nursing Homes in Phase 3 Trial americanpharmaceuticalreview
January 22, 2021
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company announced.
British Columbia rejects Health Canada-approved antibody drug for Covid-19 pharmaceutical-technology
January 12, 2021
British Columbia (BC) has rejected a Health Canada-approved antibody drug, bamlanivimab, for treating Covid-19 citing very limited safety data.

Previous page 1 2 3 4 Next page